Gossypetin prevents the progression of nonalcoholic steatohepatitis by regulating oxidative stress and AMP-activated protein kinase.

Abstract

Nonalcoholic steatohepatitis (NASH) is severe liver metabolic disorder, however, there are still no effective and safe drugs for its treatment. Previous clinical trials used various therapeutic approaches to target individual pathological mechanisms, but these approaches were unsuccessful because of the complex pathological causes of NASH. Combinatory therapy in which two or more drugs are administered simultaneously to patients with NASH, however, it carries the risk of side effects associated with each individual drug. To solve this problem, we identified gossypetin as an effective dual-targeting agent that activates AMP-activated protein kinase (AMPK) and decreases oxidative stress. Administration of gossypetin decreased hepatic steatosis, lobular inflammation and liver fibrosis in the liver tissue of mice with CDHFD and MCD diet-induced NASH. Gossypetin functioned directly as anti-oxidant agents, decreasing hydrogen peroxide and palmitate-induced oxidative stress in the AML12 cells and liver tissue of MCD diet fed mice without regulating the antioxidant response factors. In addition, gossypetin acted as a novel AMPK activator by binding to the allosteric drug and metabolite (ADaM) site, which stabilizes the activated structure of AMPK. Our findings demonstrate that gossypetin has the potential to serve as a novel therapeutic agent for NAFLD/NASH. Significance Statement This study demonstrates that gossypetin has preventive effect to progression of NASH as a novel AMPK activator and antioxidants. Our findings implicate that simultaneous activation of AMPK and oxidative stress using gossypetin has the potential to serve as a novel therapeutic approach for NAFLD/NASH patients.